鹿角霜治疗恶性肿瘤放化疗后白细胞减少症的临床疗效及安全性评价

Clinical efficacy and safety evaluation of cornu cervi degelatinatum in the treatment of leukopenia after chemoradiotherapy of malignant tumor

目的评价鹿角霜治疗恶性肿瘤放化疗后白细胞减少症的临床疗效及安全性。方法将60例恶性肿瘤放化疗后白细胞减少症、中医辨证为肾阳虚的患者随机分为试验组30例和对照组30例。对照组予以口服利可君40 mg,每日3次;试验组予以口服鹿角霜颗粒100 g,每天1次。2组患者1个疗程为2周,均服药3个疗程。比较2组治疗前后的白细胞数量、临床疗效以及不良反应发生率。结果治疗后,试验组总有效率为86.67%明显高于对照组73.33%(P<0.05)。治疗后,2组患者白细胞数量较治疗前均明显上升(P<0.05),且试验组白细胞数量明显高于对照组(P<0.05)。2组患者的不良反应发生率比较差异无统计学意义(P>0.05)。结论鹿角霜相比于利可君治疗恶性肿瘤放化疗后白细胞减少症的疗效更佳,且无明显不良反应,值得在临床中推广。

Objective To evaluate clinical efficacy of cornu cervi degelatinatum in treating leucopenia after malignant tumor chemoradiotherapy.Methods Sixty cases with leucopenia after malignant tumor chemoradiotherapy and kidney yang deficiency in Chinese medicine were randomly divided into treatment group and control group,30 cases in each group.Patients in control group were treated with leucogen 40 mg once,3 times a day. Patients in treatment group were treated with cornu cervi degelatinatum 100 g once a day. Two weeks for a course,and both groups were treated for 3 courses. The leukocyte account before and after treatment and the clinical effect after treatment of two groups were compared,also the security was evaluated. Results The total effective rate was86. 67% in treatment group,much higher than 73. 33% in control group（ P〈0. 05）. The leukocyte number apparently rised after treatment in both groups（ P〈0. 05）,while in treatment group,it rised to much higher than that in control group（ P〈0. 05）. The incidence of adverse drug reactions of the two groups was compared,and the difference was not statistically significant（ P〉0. 05）. Conclusion Compared to leucogen,cornu cervi degelatinatum has better clinical effect on the treatment of leucopenia after malignant tumor chemoradiotherapy with good security,which is worth recommended in clinical.